A Treat-to-Target Strategy Guided by Pan-Enteric Evaluation in Children With Crohn’s Disease Improves Outcomes at 2 Years
Inflammatory Bowel Diseases · 2024
DOI: 10.1093/ibd/izad173 ↗Kurz gefasst
Fachartikel in der Zeitschrift Inflammatory Bowel Diseases, 2024. Verfasst von Giulia D'Arcangelo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, Sapienza University of Rome, Rome, Italy. Hauptthemen laut MEDLINE: Crohn Disease, Remission Induction, Capsule Endoscopy. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 21 Literaturangaben.
Themen: Kinderkrankenpflege
Abstract (Originalsprache)
Background and Aims It is uncertain whether a treat-to-target approach could be an effective strategy for improving outcomes in children with Crohn’s disease (CD). Previously, we reported mucosal healing (MH) and deep remission rates throughout the intestinal tract by performing 3 pan-enteric capsule assessments and using a treat-to-target strategy over 52 weeks in children with CD. This report describes the outcomes of this approach at 104 weeks.
Methods
Children with known CD who completed the 52-week protocol repeated pan-enteric capsule endoscopy (PCE) at 104 weeks. Results at weeks 52 and 104 were compared, and long-term outcomes between patients, with and without MH, were calculated using an intention-to-treat analysis of clinical relapse, need for steroids, treatment escalation, hospitalization, and surgery.
Results
Of the previous study cohort of 48 patients, 46 (96%) were available for this extension study (28 [61%] of 46 with MH and 18 [39%] of 46 without MH at 52 weeks). When evaluated at 104 weeks, MH was maintained in 93% of patients with MH at 52 weeks. In the intention-to-treat analysis, complete MH at 52 weeks was associated with reduced risk of steroid use (log-rank P < .0001), treatment escalation (log-rank P < .0001), hospitalization (log-rank P < .0001), and clinical relapse (log-rank P < .0001).
Conclusions
When a PCE-based, treat-to-target strategy is employed, MH is sustainable (93%) over a 1-year period and is correlated with improved patient outcomes, including reduced need for steroids, treatment escalation, hospitalization, and clinical relapses at 104 weeks. ClinicalTrials.gov number: NCT03161886.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pediatric Gastroenterology and Liver Unit, Maternal and Child Health Department, Sapienza University of Rome, Rome, Italy.
- Department of Radiological Sciences, Oncology, and Pathology, Sapienza University of Rome, Rome, Italy.
- Department of Gastroenterology, IRCCS Humanitas Research Hospital, Rozzano, Italy.
- Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy.
- Pediatric Intensive Care Unit, Maternal and Child Health Department, Sapienza University of Rome, Rome, Italy.
- Children's Center for Digestive Health Care, Children's Healthcare of Atlanta, and Emory University, Atlanta, Georgia, United States.
ORCID-Profile: Salvatore Oliva
Zitieren
APA
D'Arcangelo, G., Russo, G., Aloi, M., Ruggiero, C., Maccioni, F., Hassan, C., Papoff, P., Cohen, S. A., & Oliva, S. (2024). A Treat-to-Target Strategy Guided by Pan-Enteric Evaluation in Children With Crohn’s Disease Improves Outcomes at 2 Years. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izad173
Vancouver
D'Arcangelo G, Russo G, Aloi M, Ruggiero C, Maccioni F, Hassan C, et al. A Treat-to-Target Strategy Guided by Pan-Enteric Evaluation in Children With Crohn’s Disease Improves Outcomes at 2 Years. Inflammatory Bowel Diseases. 2024. doi:10.1093/ibd/izad173
BibTeX
@article{DArcangelo2024,
author = {D'Arcangelo, Giulia and Russo, Giusy and Aloi, Marina and Ruggiero, Cosimo and Maccioni, Francesca and Hassan, Cesare and Papoff, Paola and Cohen, Stanley Allen and Oliva, Salvatore},
title = {A Treat-to-Target Strategy Guided by Pan-Enteric Evaluation in Children With Crohn’s Disease Improves Outcomes at 2 Years},
journal = {Inflammatory Bowel Diseases},
year = {2024},
doi = {10.1093/ibd/izad173}
}
EUVIMED